1. Home
  2. ETJ vs PHAR Comparison

ETJ vs PHAR Comparison

Compare ETJ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETJ
  • PHAR
  • Stock Information
  • Founded
  • ETJ 2007
  • PHAR 1988
  • Country
  • ETJ United States
  • PHAR Netherlands
  • Employees
  • ETJ N/A
  • PHAR N/A
  • Industry
  • ETJ Finance Companies
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ETJ Finance
  • PHAR Health Care
  • Exchange
  • ETJ Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • ETJ 578.8M
  • PHAR 731.1M
  • IPO Year
  • ETJ N/A
  • PHAR N/A
  • Fundamental
  • Price
  • ETJ $8.92
  • PHAR $10.42
  • Analyst Decision
  • ETJ
  • PHAR Strong Buy
  • Analyst Count
  • ETJ 0
  • PHAR 3
  • Target Price
  • ETJ N/A
  • PHAR $30.00
  • AVG Volume (30 Days)
  • ETJ 175.6K
  • PHAR 3.5K
  • Earning Date
  • ETJ 01-01-0001
  • PHAR 07-31-2025
  • Dividend Yield
  • ETJ 8.30%
  • PHAR N/A
  • EPS Growth
  • ETJ N/A
  • PHAR N/A
  • EPS
  • ETJ N/A
  • PHAR N/A
  • Revenue
  • ETJ N/A
  • PHAR $320,708,000.00
  • Revenue This Year
  • ETJ N/A
  • PHAR $13.31
  • Revenue Next Year
  • ETJ N/A
  • PHAR $7.68
  • P/E Ratio
  • ETJ N/A
  • PHAR N/A
  • Revenue Growth
  • ETJ N/A
  • PHAR 24.13
  • 52 Week Low
  • ETJ $7.20
  • PHAR $6.65
  • 52 Week High
  • ETJ $8.47
  • PHAR $12.61
  • Technical
  • Relative Strength Index (RSI)
  • ETJ 54.47
  • PHAR 48.06
  • Support Level
  • ETJ $8.60
  • PHAR $9.99
  • Resistance Level
  • ETJ $9.02
  • PHAR $10.49
  • Average True Range (ATR)
  • ETJ 0.07
  • PHAR 0.33
  • MACD
  • ETJ -0.01
  • PHAR -0.11
  • Stochastic Oscillator
  • ETJ 43.48
  • PHAR 29.19

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: